Topical therapies for psoriasis: Evidence-based review

Canadian Family Physician

Volumn 51, Issue APR., 2005, Pages 519-525

  Afifi, Tarek ^b   de Gannes, Gillian ^b   Huang, Changzheng ^b   Zhou, Youwen ^a  

^a Division of Dermatology   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMCINONIDE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL; CORTICOSTEROID; DESONIDE; DESOXIMETASONE; DITHRANOL; DRUG RECEPTOR; FLUOCINONIDE; HALCINONIDE; HYDROCORTISONE; HYDROCORTISONE VALERATE; MOMETASONE FUROATE; PLACEBO; PREDNICARBATE; PSORALEN; RETINOIC ACID RECEPTOR; RETINOID; SALICYLIC ACID; STEROID; TACALCITOL; TAR; TAZAROTENE; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ACNE; ADRENAL SUPPRESSION; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; ERYTHEMA; EVIDENCE BASED MEDICINE; FOLLICULITIS; HUMAN; HYPERCALCEMIA; INFORMATION PROCESSING; IRRITANT DERMATITIS; MEDICAL LITERATURE; MEDICAL RESEARCH; MORBIDITY; OUTPATIENT CARE; PATHOGENESIS; PERIORAL DERMATITIS; PHOTOTOXICITY; PRURITUS; PSORIASIS; REVIEW; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN CANCER; SKIN MANIFESTATION; STRIA; TACHYPHYLAXIS; TELANGIECTASIA;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANTHRALIN; ANTI-INFLAMMATORY AGENTS; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; HUMANS; PSORIASIS; RETINOIDS; TARS; VITAMIN D;

EID: 17244378287     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002;146:351-64.
2. Greaves MW, Weinstein GD. Treatment of psoriasis. Drug Ther 1995;332(9):581-7.
3. Endzweig-Gribetz CH, Brady C, Lynde C, Sibbald D, Lebwohl M. Drug interactions in psoriasis: the pros and cons of combining topical psoriasis therapies. J Cutan Med Surg 2002;6(3 Suppl):12-6.
4. Tremblay JF, Bissonnette R. Topical agents for the treatment of psoriasis, past, present and future. J Cutan Med Surg 2002;6(3 Suppl):8-11.
5. Stoughton RB. Vasoconstrictor activity and percutaneous absorption of glucocorticosteroids. Arch Dermatol 1969;99:753-6.
6. Lebwohl M, Sherer D, Washenik K, Krueger GG, Menter A, Koo J, et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 2002;41:269-74.
7. Stein LF, Sherr A, Solodkina G, Gottlieb AB, Chaudhari U. Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 2001;5(4):303-7.
8. Katz HI, Hien NT, Prawer SE. Superpotent topical steroid treatment of psoriasis vulgaris - clinical efficacy and adrenal function. J Am Acad Dermatol 1987;16:804-11.
9. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol 1986;115:475-84.
10. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB Jr. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003;9(1):2.
11. Katz HI, Prawer SE, Medansky RS, Krueger GG, Mooney JJ, Jones ML, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multi-center trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991;183:269-314.
12. Lebwohl MG, Tan MH, Meador SL, Singer G. Limited application of fluticasone propionate ointment 0.005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 2001;44:77-82.
13. Du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 1975;111:581-3.
14. Miller JJ, Roling D, Margolis D, Guzzo C. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol 1999;41:546-9.
15. 3: a cell biologic study. Br J Dermatol 1993;128:666-73.
16. 3) treatment of psoriasis: an immunohistological evaluation. Acta Derm Venereol (Stockh) 1997;77:268-72.
17. Kragballe K, Gjertsen BT, De Hoop D, Karlsmark T, van de Kerkhof PC, Larko O, et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991;337:193-6.
18. Cunliffe WJ, Berth-Jones J, Claudy A, Fairiss G, Goldin D, Gratton D, et al. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992;26:736-43.
19. Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatol Treat 2003;14(1):8-13.
20. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487-502.
21. Mortensen L, Kragballe K, Wegmann E, Schifter S, Risteli J, Charles P. Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism: a randomized, double-blind, placebo-controlled study. Acta Derm Venereol (Stockh) 1993;73:300-4.
22. Duvic M, Nagpal S, Asano AT, Chandraratna RA. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol 1997;37(2 Pt 3):S18-S24.
23. Weinstein GD, Krueger GG, Lowe NJ, Duvic M, Friedman DJ, Jegasothy BV, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92.
24. Weinstein GD, Koo JY, Krueger GG. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003;48:760-7.
25. Lebwohl M, Ast E, Callen JP. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;38:705-11.
26. Runne U, Kunze J. Short duration ("minutes") therapy with dithranol for psoriasis: a new outpatient regimen. Br J Dermatol 1982;106:135-9.
27. Volden G, Bjornberg A, Tegner E, Pedersen NB, Arles UB, Agren S, et al. Short-contact treatment at home with Micanol. Acta Derm Venereol Suppl (Stockh) 1992;172:20-2.
28. Ramsay B, Lawrence CM, Bruce JM, Shuster S. The effects of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol 1990;23:73-6.
29. Walter JF, Stoughton RB, DeQuoy PR. Suppression of epidermal proliferation by ultraviolet light, coal tar and anthralin. Br J Dermatol 1978;99:89-96.
30. Sharma V, Kaur I, Kumar B. Calcipotriol versus coal tar: a prospective randomized study in stable plaque psoriasis. Int J Dermatol 2003;42:834-8.
31. Tzaneva S, Honigsmann H, Tanew A. Observer-blind, randomized, intrapatient comparison of a novel 1% coal tar preparation (Exorex) and calcipotriol cream in the treatment of plaque type psoriasis. Br J Dermatol 2003;149:350-3.
32. Jemec GBE, Osterlind A. Cancer in patients treated with coal tar: a long-term follow up study. J Eur Acad Dermatol Venereol 1994;3(2):153-6.
33. Kragballe K, Barnes L, Hamber KJ. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998;139:649-54.
34. Austad J, Bjerke JR, Gjertsen BT. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis. J Eur Acad Dermatol Venereol 1998;11(1):19-24.
35. Papp KA, Guenther L, Boyden B. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54.
36. Lebwohl MG, Breneman DL, Goffe BS. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;39:590-6.
37. Lebwohl M, Lombardi K, Tan MH. Duration of improvement of psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatments. Int J Dermatol 2001;40:64-6.
38. Kaidbey K, Kopper SC, Sefton J, Gibson JR. A pilot study to determine the effect of tazarotene 0.1% gel on steroid-induced epidermal atrophy. Int J Dermatol 2001;40:468-71.
39. Koo J, Cuffie CA, Tanner DJ, Bressinck R. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 1998;20(2):283-91.